From Our Partners
Tuesday, July 5, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

The Illumina Example: DTRA as a Catalyst for Biotech Growth

by Global Biodefense Staff
December 11, 2012
DTRA Counter-WMD Research

A recent article published by the Department of Defense highlights the Defense Threat Reduction Agency’s Chemical and Biological Technologies Department (DTRA CB) contributions to the economy and technology advancements by providing the spark companies need to further development by the deeper pockets of venture capital.

The article cites the development of the Illumina, Inc. product line for genotyping, gene expression, copy-number variation and methylation analyses. “That started with early funding of work at Tufts University using a bead array concept as an analysis tool. Later, the bead arrays were diversified in their application to vapor sensing, which was funded through the Defense Advanced Research Projects Agency’s (DARPA) ‘Dog’s Nose program,’ an advanced, field-portable system for detecting land mines.”

The full line of Illumina products is now in wide use by not only the researchers at the Department of Defense, but at many other federal laboratories and major genome centers around the world.

Nels Olson, Ph.D., DTRA CB’s thrust coordinator for Sensing and Reporting and the Diagnostics Division’s senior advisor on biotechnology reagents, instruments and disposables, explains that while DTRA CB investments might be just a few million dollars, venture capitalists see it as a vetting process that proves the concept and encourages them to make the much larger investments. The government benefits when these innovations reach commercialization levels and are able to be purchased to protect warfighters in the field.

“DTRA can come up with some money to get the research going,” says Olson. “But it’s the $100-200 million investments by private capital after we show the idea will work that get the factories built and the technology cranked out at a viable cost to consumers, including DTRA.”

Read more at DVIDS: DTRA-CB initial investment money helps grow development

From Our Partners
Tags: Defense Threat Reduction Agency

Related Posts

Send in the Blow Flies: Using Insects to Sample Areas for Chemical Warfare Agents
CBRNE

Send in the Blow Flies: Using Insects to Sample Areas for Chemical Warfare Agents

April 11, 2022
Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses
Pathogens

Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses

April 11, 2022
Emergency Response Missions for Recovered Chemical Warfare Material
CBRNE

Emergency Response Missions for Recovered Chemical Warfare Material

March 13, 2022
Radiation Countermeasures: Q-3-R Alleviates Radiation-Induced Lung Inflammation and Fibrosis
CBRNE

Radiation Countermeasures: Q-3-R Alleviates Radiation-Induced Lung Inflammation and Fibrosis

February 27, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC